As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...
An investigator-initiated trial examining YolTech Therapeutics’ in vivo gene editing-based ‘life-long cure’ for patients living with a rare genetic disorder has seen the treatment able to ...
The YOLT-203 in-vivo gene editing therapy was developed to treat patients living with primary hyperoxaluria type 1 (PH1), a condition caused by a genetic deficiency in the liver enzyme alanine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback